Table 1.
Patient characteristics with disease type, laboratory parameters, CART cell product including previous therapy, and toxicity treatment
| Count | Median | Range | |
| Age (years) at the time of CART infusion | 58 | 26–75 years | |
| Sex (F:M) | 6:8 | ||
| ECOG performance status | 1 | 0–2 | |
| Ann Arbor stage | IV | I–IV | |
| Disease type | |||
| DLBCL | 6 patients | ||
| DLBCL with CNS involvement | 3 of 6 patients | ||
| tFL | 3 patients | ||
| MCL with CNS involvement | 2 patients | ||
| Lymphoblastic lymphoma | 1 patient | ||
| Burkitt lymphoma | 1 patient | ||
| PMBCL | 1 patient | ||
| Peak ICANS | 3 | 1–5 | |
| Peak CRS | 2 | 1–4 | |
| Peak LDH | 524 U/L | 163–17624 U/L (norm 110–220 U/L) | |
| CART cell product | |||
| Axicabtagene ciloleucel—Yescarta | 7 patients | ||
| Tisagenlecleucel—Kymriah | 7 patients | ||
| Previous treatment | |||
| Previous treatment lines | 4 | 2–8 | |
| Previous ASCT | 2 patients | 0 | |
| Hospitalization days | 20.5 days | 11–29 days | |
| Toxicity treatment | |||
| Corticosteroid start (after CART infusion) | 14 of 14 | 4.5 days | 1–25 days |
| Cumulative dexamethasone dose | 14 of 14 | 297 mg | 26–1228 mg |
| Cumulative dexamethasone days | 14 of 14 | 12.5 days | 3–26 days |
| Anakinra start (after CART infusion) | 14 of 14 | 8.5 days | 5–23 days |
| Anakinra dose (100–200 mg subcutaneous) | 14 of 14 | 3 times | 1–3 times |
| Number of patients with CRS grade ≥2 | 7 of 14 | ||
| Number of patients treated with tocilizumab: | 7 of 14 | ||
| Tocilizumab start (after CART infusion) | 7 of 7 | 4 days | 1–12 days |
| Tocilizumab dose (times 8 mg/kg) | 7 of 7 | 2 times | 1–3 times |
| Survival | |||
| Patients alive (%) | 29 | ||
| Patients alive (n) | 4 | ||
| Patients deceased (%) | 71 | ||
| Day of death | 29th day | 18–198 days | |
| Cause of death | 6 of 10 PDs | ||
| 3 of 10 Infections* | |||
| 1 of 10 ICANS 5 | |||
| Infections* | |||
| Fungal infection | |||
| 1 patient: mucormycosis | |||
| Coinfection of fungi and bacteria: | |||
| 1 patient: Candida albicans and Pseudomonas aeruginosa | |||
| 1 patient: Enterococcus faecalis and fungal infection based on 1–3 beta glucan test | |||
Hospitalization days from CART infusion (day 0) to discharge are indicated.
ASCT, autologous stem cell transplantation; CNS, central nervous system; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; ICANS, immune effector cell-associated neurotoxicity syndrome; LDH, lactate dehydrogenase; MCL, mantle cell lymphoma; PD, progressive disease; PMBCL, primary mediastinal B-cell lymphoma; tFL, transformed follicular lymphoma.